SFXN3

Summary

SFXN3 (sideroflexin 3, HGNC:16087) is a protein-coding gene on chromosome 10q24.31, encoding Sideroflexin-3 (Q9BWM7). Mitochondrial serine transporter that mediates transport of serine into mitochondria, an important step of the one-carbon metabolism pathway.

Enables L-serine transmembrane transporter activity. Involved in serine import into mitochondrion. Located in mitochondrion.

Source: NCBI Gene 81855 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 60 total
• Druggable target: yes
• MANE Select transcript: NM_030971

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16087
Approved symbol	SFXN3
Name	sideroflexin 3
Location	10q24.31
Locus type	gene with protein product
Status	Approved
Aliases	SFX3, SLC56A3
Ensembl gene	ENSG00000107819
Ensembl biotype	protein_coding
OMIM	615571
Entrez	81855

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 16 protein_coding, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000393459, ENST00000465383, ENST00000466982, ENST00000470252, ENST00000487721, ENST00000489434, ENST00000698791, ENST00000698792, ENST00000896238, ENST00000896239, ENST00000896240, ENST00000896241, ENST00000896242, ENST00000896243, ENST00000896244, ENST00000954850, ENST00000954851, ENST00000954852, ENST00000954853, ENST00000954854, ENST00000954855

RefSeq mRNA: 10 — MANE Select: NM_030971 NM_001388027, NM_001388028, NM_001388029, NM_001388030, NM_001388031, NM_001388032, NM_001388033, NM_001388034, NM_001388035, NM_030971

CCDS: CCDS7508

Canonical transcript exons

ENST00000393459 — 12 exons

Exon	Start	End
ENSE00000721559	101038643	101038692
ENSE00001406456	101039489	101041241
ENSE00001428431	101031234	101031534
ENSE00003461712	101034692	101034855
ENSE00003472062	101037382	101037431
ENSE00003483735	101035497	101035667
ENSE00003485813	101037076	101037203
ENSE00003492264	101039175	101039222
ENSE00003496935	101036003	101036101
ENSE00003519470	101036486	101036561
ENSE00003524033	101032314	101032482
ENSE00003558491	101036723	101036808

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 98.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.9307 / max 145.0037, expressed in 1753 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106630	9.2900	1663
106635	9.1649	1572
106636	5.2887	1468
106634	1.2285	797
106632	0.4518	228
106633	0.4052	220
106631	0.0569	15
205970	0.0356	8
106637	0.0090	3

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar hemisphere	UBERON:0002245	98.19	gold quality
cerebellar cortex	UBERON:0002129	98.18	gold quality
tendon of biceps brachii	UBERON:0008188	98.16	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.10	gold quality
cerebellum	UBERON:0002037	97.88	gold quality
paraflocculus	UBERON:0005351	97.45	gold quality
saphenous vein	UBERON:0007318	97.00	gold quality
pancreatic ductal cell	CL:0002079	96.53	gold quality
ascending aorta	UBERON:0001496	96.46	gold quality
thoracic aorta	UBERON:0001515	96.44	gold quality
descending thoracic aorta	UBERON:0002345	96.39	gold quality
cerebellar vermis	UBERON:0004720	96.20	gold quality
synovial joint	UBERON:0002217	96.14	gold quality
right coronary artery	UBERON:0001625	96.04	gold quality
vein	UBERON:0001638	95.86	gold quality
jejunal mucosa	UBERON:0000399	95.83	gold quality
aorta	UBERON:0000947	95.70	gold quality
cardia of stomach	UBERON:0001162	95.70	gold quality
skin of leg	UBERON:0001511	95.68	gold quality
nipple	UBERON:0002030	95.57	gold quality
small intestine Peyer’s patch	UBERON:0003454	95.43	gold quality
stromal cell of endometrium	CL:0002255	95.36	gold quality
small intestine	UBERON:0002108	95.31	gold quality
duodenum	UBERON:0002114	95.19	gold quality
coronary artery	UBERON:0001621	95.17	gold quality
popliteal artery	UBERON:0002250	95.15	gold quality
tibial artery	UBERON:0007610	95.15	gold quality
left coronary artery	UBERON:0001626	95.07	gold quality
endocervix	UBERON:0000458	95.04	gold quality
mucosa of stomach	UBERON:0001199	95.03	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.09

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYC

miRNA regulators (miRDB)

108 targeting SFXN3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-30B-3P	99.70	65.76	2325

Literature-anchored findings (GeneRIF, showing 3)

• Non-coding RNA-mediated high expression of SFXN3 as a prognostic biomarker associated with paclitaxel resistance and immunosuppressive microenvironment in head and neck cancer. (PMID:36159813)
• SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid Leukemia Patients. (PMID:37491851)
• Association of poly(rC)-binding protein-2 with sideroflexin-3 through TOM20 as an iron entry pathway to mitochondria. (PMID:38599240)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	sfxn3	ENSDARG00000057374
mus_musculus	Sfxn3	ENSMUSG00000025212
rattus_norvegicus	Sfxn3	ENSRNOG00000015442
drosophila_melanogaster	Sfxn1-3	FBGN0037239
caenorhabditis_elegans		WBGENE00007080
caenorhabditis_elegans		WBGENE00008137
caenorhabditis_elegans		WBGENE00009513
caenorhabditis_elegans		WBGENE00011440
caenorhabditis_elegans		WBGENE00012402

Paralogs (4): SFXN5 (ENSG00000144040), SFXN2 (ENSG00000156398), SFXN1 (ENSG00000164466), SFXN4 (ENSG00000183605)

Protein

Protein identifiers

Sideroflexin-3 — Q9BWM7 (reviewed: Q9BWM7)

All UniProt accessions (4): Q9BWM7, A0A8V8TM72, A0A8V8TP06, S4R3N9

UniProt curated annotations — full annotation on UniProt →

Function. Mitochondrial serine transporter that mediates transport of serine into mitochondria, an important step of the one-carbon metabolism pathway. Mitochondrial serine is converted to glycine and formate, which then exits to the cytosol where it is used to generate the charged folates that serve as one-carbon donors.

Subcellular location. Mitochondrion membrane.

Similarity. Belongs to the sideroflexin family.

RefSeq proteins (10): NP_001374956, NP_001374957, NP_001374958, NP_001374959, NP_001374960, NP_001374961, NP_001374962, NP_001374963, NP_001374964, NP_112233* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004686	Mtc	Family

Pfam: PF03820

Catalyzed reactions (Rhea), 1 shown:

• L-serine(in) = L-serine(out) (RHEA:35031)

UniProt features (6 total): transmembrane region 4, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BWM7-F1	87.55	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 200 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_AMINO_ACID_TRANSMEMBRANE_TRANSPORT, GOBP_MITOCHONDRIAL_TRANSPORT, RODRIGUES_NTN1_TARGETS_DN, GOBP_ORGANIC_ACID_TRANSPORT, GOBP_MITOCHONDRIAL_TRANSMEMBRANE_TRANSPORT, ONKEN_UVEAL_MELANOMA_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, MARTINEZ_RB1_TARGETS_DN, BLALOCK_ALZHEIMERS_DISEASE_UP, MODULE_206, GOBP_ONE_CARBON_METABOLIC_PROCESS, GOBP_AMINO_ACID_TRANSPORT, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP

GO Biological Process (8): one-carbon metabolic process (GO:0006730), serine import into mitochondrion (GO:0140300), mitochondrial transmembrane transport (GO:1990542), monoatomic ion transport (GO:0006811), amino acid transport (GO:0006865), L-serine transport (GO:0015825), monoatomic ion transmembrane transport (GO:0034220), transmembrane transport (GO:0055085)

GO Molecular Function (4): monoatomic ion transmembrane transporter activity (GO:0015075), L-serine transmembrane transporter activity (GO:0015194), transmembrane transporter activity (GO:0022857), protein binding (GO:0005515)

GO Cellular Component (4): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), membrane (GO:0016020), mitochondrial membrane (GO:0031966)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transmembrane transport	3
transport	3
serine transport	2
small molecule metabolic process	1
amino acid transmembrane transport	1
import into the mitochondrion	1
carboxylic acid transmembrane transport	1
mitochondrial transport	1
L-amino acid transport	1
monoatomic ion transport	1
cellular process	1
transmembrane transporter activity	1
monoatomic ion transmembrane transport	1
L-amino acid transmembrane transporter activity	1
L-serine transport	1
transporter activity	1
binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
cellular anatomical structure	1
mitochondrion	1
mitochondrial envelope	1
organelle membrane	1

Protein interactions and networks

STRING

722 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SFXN3	SLC25A38	Q96DW6	472
SFXN3	ZNF85	Q03923	456
SFXN3	CREG2	Q8IUH2	454
SFXN3	ZNF708	P17019	452
SFXN3	ZNF28	P17035	450
SFXN3	ZNF572	Q7Z3I7	450
SFXN3	SREK1IP1	Q8N9Q2	450
SFXN3	PMP2	P02689	414
SFXN3	GNG12	Q9UBI6	414
SFXN3	LEMD3	Q9Y2U8	404
SFXN3	PDZD7	Q9H5P4	397
SFXN3	WIPF1	O43516	393
SFXN3	P2RX1	P51575	386
SFXN3	TLR4	O00206	384
SFXN3	ZNF430	Q9H8G1	383

IntAct

202 interactions, top by confidence:

A	B	Type	Score
SFXN3	SCN3B	psi-mi:“MI:0915”(physical association)	0.740
NDUFS3	NDUFS8	psi-mi:“MI:0914”(association)	0.730
CFTR	XPO1	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
SFXN3	LAMP2	psi-mi:“MI:0914”(association)	0.670
SFXN3	LAMP2	psi-mi:“MI:0915”(physical association)	0.670
TOMM22	XRCC3	psi-mi:“MI:0914”(association)	0.640
TRIM16L	CCDC22	psi-mi:“MI:0914”(association)	0.640
TRIM16L	SFXN3	psi-mi:“MI:0915”(physical association)	0.620
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
SFXN3	EBP	psi-mi:“MI:0915”(physical association)	0.560
SFXN3	ZDHHC15	psi-mi:“MI:0915”(physical association)	0.560
SFXN3	TMEM14B	psi-mi:“MI:0915”(physical association)	0.560
SFXN3	HSD17B11	psi-mi:“MI:0915”(physical association)	0.560
REEP4	SFXN3	psi-mi:“MI:0915”(physical association)	0.560
SFXN3	RETREG3	psi-mi:“MI:0915”(physical association)	0.560
SFXN3	TMEM51	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (201): SFXN3 (Affinity Capture-RNA), SFXN3 (Affinity Capture-RNA), SFXN3 (Affinity Capture-MS), SFXN3 (Affinity Capture-MS), SFXN3 (Affinity Capture-MS), SFXN3 (Affinity Capture-MS), SFXN3 (Affinity Capture-MS), ZMYM2 (Affinity Capture-MS), TARBP2 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), SFXN3 (Affinity Capture-MS), SFXN3 (Co-fractionation), SFXN3 (Co-fractionation), SFXN3 (Two-hybrid), SFXN3 (Affinity Capture-MS)

ESM2 similar proteins: A0A067XMT5, A0A194XJW1, A0A1V6NWP3, A0A1W5T1Y3, A0A2I1C3V3, A0A411PQQ5, A0A455LLW7, A0A455M7R7, A0A4P8DK01, A0A7L9EYL3, A0A8F4NWB9, A0A8F4S8P5, A1L2F6, A4DA06, A4DA85, A6RH42, B0D4E6, B2ATB0, B8NI03, C0NIJ2, C6H7W0, D1Z4K7, D4D802, E3Q717, E4UPP6, I1RAL7, M1VWN5, M2WJF5, M3APK4, O13793, P0DOB2, P37295, P9WEV9, Q06089, Q0TVF9, Q0V6M5, Q12029, Q28GF8, Q2U4X9, Q4WQY6

Diamond homologs: A5A761, A6QP55, B2LU20, O13793, Q09201, Q12029, Q54NQ9, Q5E9M8, Q5EA43, Q5FC79, Q5RD16, Q63965, Q8CFD0, Q8TD22, Q91V61, Q925N0, Q925N2, Q96NB2, Q99JR1, Q9BWM7, Q9H9B4, Q9JHY2, Q9VN13, Q9VVW3, A8E7G5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1735 predictions. Top by Δscore:

Variant	Effect	Δscore
10:101032481:GC:G	donor_gain	1.0000
10:101032483:G:GG	donor_gain	1.0000
10:101034687:TGCA:T	acceptor_loss	1.0000
10:101034689:CAGAA:C	acceptor_loss	1.0000
10:101034690:A:AC	acceptor_loss	1.0000
10:101034690:A:AG	acceptor_gain	1.0000
10:101034691:G:GA	acceptor_gain	1.0000
10:101034691:GA:G	acceptor_gain	1.0000
10:101034691:GAA:G	acceptor_gain	1.0000
10:101034691:GAAA:G	acceptor_gain	1.0000
10:101034691:GAAAA:G	acceptor_gain	1.0000
10:101034852:ACAG:A	donor_loss	1.0000
10:101034856:G:C	donor_loss	1.0000
10:101036483:CAG:C	acceptor_loss	1.0000
10:101036484:A:AG	acceptor_gain	1.0000
10:101036484:A:T	acceptor_loss	1.0000
10:101036485:G:GA	acceptor_loss	1.0000
10:101036485:G:GG	acceptor_gain	1.0000
10:101036485:GGC:G	acceptor_gain	1.0000
10:101036485:GGCA:G	acceptor_gain	1.0000
10:101036558:CAAG:C	donor_loss	1.0000
10:101036561:GGTAA:G	donor_loss	1.0000
10:101036562:GTAA:G	donor_loss	1.0000
10:101036563:T:A	donor_loss	1.0000
10:101036806:GAG:G	donor_gain	1.0000
10:101037071:TGCA:T	acceptor_loss	1.0000
10:101037073:CA:C	acceptor_loss	1.0000
10:101037073:CAGAG:C	acceptor_gain	1.0000
10:101037074:A:AC	acceptor_loss	1.0000
10:101037074:A:AG	acceptor_gain	1.0000

AlphaMissense

2083 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:101036051:T:A	N127K	0.999
10:101036051:T:G	N127K	0.999
10:101036063:C:A	N131K	0.999
10:101036063:C:G	N131K	0.999
10:101034762:G:C	R23T	0.998
10:101034763:A:C	R23S	0.998
10:101034763:A:T	R23S	0.998
10:101035632:C:A	N99K	0.998
10:101035632:C:G	N99K	0.998
10:101036039:T:A	N123K	0.998
10:101036039:T:G	N123K	0.998
10:101036788:C:A	N191K	0.998
10:101036788:C:G	N191K	0.998
10:101036802:G:C	R196T	0.998
10:101036802:G:T	R196M	0.998
10:101038685:G:C	G272R	0.998
10:101038686:G:A	G272D	0.998
10:101039576:G:C	K319N	0.998
10:101039576:G:T	K319N	0.998
10:101035606:C:A	R91S	0.997
10:101036031:T:A	W121R	0.997
10:101036031:T:C	W121R	0.997
10:101036046:T:C	F126L	0.997
10:101036048:C:A	F126L	0.997
10:101036048:C:G	F126L	0.997
10:101036803:G:C	R196S	0.997
10:101036803:G:T	R196S	0.997
10:101037177:G:C	R232T	0.997
10:101037177:G:T	R232I	0.997
10:101034773:T:C	F27L	0.996

dbSNP variants (sampled 300 via entrez): RS1001168908 (10:101031719 C>G), RS1001229174 (10:101037802 C>A,T), RS1001946635 (10:101031099 C>G,T), RS1002030211 (10:101037054 C>T), RS1002212475 (10:101031968 C>A), RS1002702850 (10:101040236 C>A,G), RS1002802726 (10:101030476 T>C), RS1003303487 (10:101034336 A>C), RS1004085639 (10:101034255 G>A), RS1004135053 (10:101030832 C>G,T), RS1004207164 (10:101030499 C>A,G), RS1004208360 (10:101040430 T>C), RS1004358709 (10:101036708 A>C), RS1004573890 (10:101038950 A>G), RS1004792913 (10:101036283 T>C)

Disease associations

OMIM: gene MIM:615571 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006921_7	Regular attendance at a pub or social club	1.000000e-08
GCST010002_298	Refractive error	3.000000e-22

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009592	social interaction measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067194 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC56 Sideroflexins

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.87	Kd	1360	nM	CHEMBL5653589
5.87	ED50	1360	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149391: Binding affinity to human SFXN3 incubated for 45 mins by Kinobead based pull down assay	kd	1.3596	uM

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
Tobacco Smoke Pollution	increases expression, decreases expression	3
Cyclosporine	decreases expression, decreases methylation	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
Leflunomide	decreases expression	2
Acetaminophen	decreases expression	2
Air Pollutants	affects cotreatment, affects expression, increases abundance, decreases expression	2
Benzo(a)pyrene	affects methylation	2
Diethylhexyl Phthalate	decreases expression, increases abundance, increases methylation, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
bisphenol F	increases expression	1
sotorasib	affects cotreatment, decreases expression	1
testosterone enanthate	affects expression	1
alpha-pinene	affects cotreatment, affects expression, increases abundance	1
uranyl acetate	affects expression	1
bisphenol A	affects expression	1
deoxynivalenol	decreases expression	1
titanium dioxide	decreases methylation	1
mono-(2-ethylhexyl)phthalate	increases abundance, increases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
potassium chromate(VI)	decreases expression	1
aflatoxin B2	increases methylation	1
methacrylaldehyde	affects cotreatment, affects expression, increases abundance	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression, affects response to substance, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
pentabromodiphenyl ether	increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
entinostat	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652433	Binding	Binding affinity to human SFXN3 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4HC	HCT116-SFXN3-KO-c4	Cancer cell line	Male
CVCL_D4HD	HCT116-SFXN3-KO-c7	Cancer cell line	Male
CVCL_TK83	HAP1 SFXN3 (-) 1	Cancer cell line	Male
CVCL_XS68	HAP1 SFXN3 (-) 2	Cancer cell line	Male
CVCL_XS69	HAP1 SFXN3 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice